Clinical Trial Update: Pramipexole for Binge Eating Disorder [Phase 3]

View source ↗

Summary

The Phase 3 trial of pramipexole for Binge Eating Disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• Pramipexole (pramipexole)

Snippet

Sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota | Conditions: Binge Eating Disorder | Phase 3 | Status: WITHDRAWN